Calcitonin
As of the edition of 20 October 2026, Calcitonin is a protein: marketed, first approved in 1976 (CH); acts on CALCR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1983
- Kind
- Protein
- Brand name
- Miacalcic
- First approved
- 17 May 1976 (CH)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Novartis; 3 holders in all
- Withdrawn from market
- 1 January 2013 (in some regions)
- Registered trials
- 11, 1 stopped early
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Hormones; Injuries; Digestive system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Calcitonin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCR | Calcitonin receptor | P30988 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 4 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 3 | 1 | 1 | 1 |
| All trials | 11 |